GNS Healthcare Blog

GNS Healthcare Primary Blog

By December 31, 1969

GNS Healthcare Blog

The Promise of Precision Medicine is Not Misleading, It’s Just Beginning

Last week, an op-ed was published in the New York Times that asked an important question: Are patients being misled by the promise of precision medicine? The article, which focused on the treatment of various forms of cancer, posited that the successes achieved through precision medicine are relatively few when compared to its failures¹.

Precision medicine is a term that has been trending for several years (just try googling it). Previously, the healthcare industry had tried other avenues to produce better outcomes at lower costs. While the hype around what precision medicine can achieve...

Read More

Making the Case for Data Diversity

The power and effectiveness of artificial intelligence (AI) and its continued integration into everyday life is becoming more widely accepted. This is especially true in healthcare where researchers are making significant strides in identifying the causes of and providing more effective treatments for major diseases.

But among these successes is a question of whether some AI results may be biased. A recent article in Fast Company acknowledges that AI should be “the great equalizer” because it is all about objective math and calculations. But the article raises the question of “creator...

Read More

A Few Fun Facts to Warm Your Labor Day

For most of us, the first Monday in September marks a day off from work and a last chance to gather with friends and family before summer is replaced by the chill of fall. Our barbecues and fireworks are a far cry from the first Labor Day celebrated in 1882, when a parade of 10,000 workers in New York City went on strike to protest the 58-hour work week that was common at the time.

It took until 1894 for Labor Day to be declared a federal holiday and until 1916 for the Adamson Act to establish the eight-hour work day. It is thanks to the efforts of these early laborers that we have...

Read More

Are value-based contracts the end of the journey or just a stop along the way?

The drive to value-based care has become a significant issue for biopharma companies as more health plans request value-based contracts. According to McKinsey, over 200 of these innovative contracts have been publicly disclosed since 1994¹. The buzz around the biopharma industry is that these value-based contracts are the wave of the future. Although this trend is likely to continue in the immediate future, the shift to these types of contracts may not survive in the long term. Precision medicine may make them obsolete.

 

Types of innovative biopharma contracts

The two most prevalent types...

Read More

Taking the Plunge: From ALS Ice Bucket Challenge to ALS Research with AI and Robust Data

If you drove around Boston in the summer of 2014, you wouldn’t be surprised to see individuals on their lawns, driveways, or in their back yards dumping buckets of ice water over their heads. The chilly act was part of a challenge that encouraged participants to film their icy shower, post it to social media, and nominate others to do the same. The nominee had 24 hours to comply or donate money to The ALS Association. Most people did both and the videos went viral, spreading across the country and, eventually, the world.

The ALS Ice Bucket Challenge was the brainchild of former Boston...

Read More

Fear versus Promise: The Conversation Continues Around AI

There is a wide and varied mix of opinions when it comes to artificial intelligence (AI). Peruse just about any publication and there’s likely to be an article or two on how AI will transform the way we live for the better or conversely how it is sure to overtake our lives in unimaginable ways.

Adding to the confusion, you have technology visionaries like Elon Musk saying, “I’m close to artificial intelligence (AI) and it scares the hell out of me”. Or Bill Gates calling AI “our biggest existential threat.”1  Given those impressions, it’s no wonder that many people today still fear the...

Read More

Talent, Data, and Tech: An Inclusive Approach to Drug Development

Interest in applying artificial intelligence and machine learning to healthcare has reached a pinnacle. Every day there are a slew of new articles and reports discussing the various ways that algorithms can transform the industry and there are many interesting technologies being developed and deployed—from digital health technologies that aim to make care delivery more patient-centric to machines that use image recognition to identify tumors before the human eye can see them.

A big area of potential growth for the use of AI is in precision medicine— the ability to customize the treatment...

Read More

All AI Is Not Equal: Why Cause and Effect is Crucial for Healthcare

Judea Pearl is not happy.

One of the pioneers of Artificial Intelligence in the 1980’s, Pearl said in a recent interview in The Atlantic that the field of AI is stuck in a world of reasoning by association and probabilistic predictions. Pearl thinks too many people are deploying AI to overcome uncertainty – predicting what will happen next by association rather than leveraging the power of the technology to deal with cause and effect. He goes on to say that AI and machine learning need to move more aggressively to evaluate interventions and causal models to gain true value1.

Healthcare...

Read More

In Honor of the 4th – A Look Back at How Far Healthcare Has Come

Healthcare and the practice of medicine has certainly come a long way since the founding of the United States in 1776. In honor of the 242nd birthday of the U.S., we thought it would be interesting to see how far we have come since our nation’s birthday.  Check out some of the major medical milestones, contributions of American scientists and relish your luck in being born during the modern medical era.

Read More

Optimizing Drug R&D: 3 Strategies to Embrace

Biopharma continues to look for ways to streamline the drug development process. With costs of bringing a drug to market now reaching $2.7 billion and the timeline stretching to nearly a decade, stakeholders across the healthcare continuum are clamoring for a faster, less expensive method. 

The drug research and development process is well established and has remained largely unchanged over the past few decades and for good reason – it works. The methodology biopharma has followed has given the world many effective drugs which are both improving the quality of life for patient as well as...

Read More

Subscribe to the GNS Blog

Recent Posts:

Twitter